Toric IOL selection

Article

Dr Kermani discusses recent results of a retrospective analysis of three different lenses and how selection of an appropriate toric IOL can be made according to a patient's reading habits

In his presentation during the Multifocals I session, Dr Kermani revealed the results of a retrospective analysis of operations he and his colleagues (Drs Georg Gerten and Uwe Oberheide) performed on 52 eyes. In total three different IOLs were implanted in the study group who had a mean age of 60 years. The patients spherical aberration ranged from +9 to -13 D and the cylinder aberration was up to -7 D. Follow-up of the patients was performed in a three month interval and in over 90% of the group.

"At the 3-month follow-up, 85% of the patients implanted with the ReSTOR toric IOL gained at least one line or more," said Dr Kermani. The clinicians also found that two-thirds of Groups I and II had a post-op uncorrected near VA of J2 or better, just over half of the ReSTOR group achieved this.

"In an overview of the vector analysis of the total astigmatism, we found that the effective reduction of the total cylinder was from -2.25 D preoperatively to -0.75 D postoperatively," he added.

Additionally, Dr Kermani and colleagues noted that Group I and Group II achieved the best reading abilities while Group III had the best intermediate and distance VA results.

Extremely satisfying surgery

"So, we believe these kinds of surgery are extremely satisfying for the patients because pre-op uncorrected VA in both refractive lens exchange and cataract surgery is usually very poor," said Dr Kermani. "Therefore, the acceptance and efficacy of these IOLs are very high."

He concluded, "The end power of the mIOL determines the outcome with regards to the predominant near, intermediate or distance VA and hence selection can be made with respect to patients' viewing habits."

Special Contributor

Dr Omid Kermani is a consultant at the Augenklinik am Neumarkt, Augenlaserzentrum Köln, Germany, and a member of OTEurope's EAB. He can be reached by Email: o.kermani@augenportal.de

Dr Kermani has indicated no financial interests in the subject matter of this article.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.